Association between genetic polymorphisms of drug-metabolizingenzymes and factors of liver cancer

药物代谢酶基因多态性与肝癌相关因素的关系

• 批准号: 22501059
• 负责人: YASUHARA Hajime
• 金额: $ 2.66万
• 依托单位: Showa University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22501059/
• 关键词: CYP2C19; 肝臓癌; 遺伝子多型; サイトカイン; 転移; 転移性肝臓癌; 遺伝子環境交互作用; 発がんメカニズム

This study was conducted to clarify the association between drug-metabolizing enzyme CYP2C19 gene mutation and liver cancer susceptibility. 21 liver and blood samples were donated from Japanese liver cancer patients who received partial hepatectomy. The results indicated that the gene mutation found in high frequency in metastatic liver cancer patients occur congenitally rather than arise in peripheral tumor site acquired by cancer condition.CYP2C19 activity decreased in all samples and the degree was associated with changes in several cytokines, but did not correlate with the genotype of the enzyme. For the prevention of metastasis and for the proper treatment of liver cancer, further studies elucidating the mechanisms and significance of the results obtained and clarifying the role of CYP2C19 in cancer patients are needed.

本研究旨在探讨药物代谢酶CYP 2C 19基因突变与肝癌易感性的关系。21份肝脏和血液样本来自接受部分肝切除术的日本肝癌患者。结果表明，转移性肝癌患者中存在的高频率基因突变是先天性的，而非肿瘤周围部位获得性的; CYP 2C 19活性在所有样本中均降低，其程度与多种细胞因子的变化有关，但与酶的基因型无关。为了预防转移和正确治疗肝癌，需要进一步研究阐明所获得的结果的机制和意义，并阐明CYP 2C 19在癌症患者中的作用。

项目成果

CYP2C19遺伝子変異と肝臓癌発症リスクの関連

CYP2C19基因突变与肝癌风险的关系

• 发表时间: 2011
• 作者: 西村有希;倉田知光;岩瀬万里子;安原 一;小林靖奈;山元俊憲;青木武士;村上雅彦;齋藤光次;小林真一
• 通讯作者: 小林真一

CYP2C19遺伝子変異の発癌への関与

CYP2C19基因突变参与癌变

• 发表时间: 2011
• 作者: 西村有希;倉田知光;岩瀬万里子;小林靖奈;山元俊憲;安原 一
• 通讯作者: 安原 一

The participation of CYP2C19 gene mutation in liver cancer

CYP2C19基因突变在肝癌中的参与

• 发表时间: 2011
• 作者: 西村有希;倉田知光;岩瀬万里子;小林靖奈;山元俊憲;安原 一;Toshihiro Tanaka and Kazuo Tamura;西村有希
• 通讯作者: 西村有希